PMVP
PMV Pharmaceuticals, Inc.
+0.03 (+2.10%)1.46USD271K成交股數78.0M市值–本益比(近四季)17.4股價營收比-53.4%營收年增(近四季)2026-11-16下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 788K-53% | 980K-49% | 1.2M-53% | 1.5M-47% | 1.7M-43% | 1.9M-39% | 2.6M-12% | 2.8M+4% | 3.0M | 3.2M | 3.0M | 2.7M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 14.7M | 15.3M | 15.8M | 18.2M | 18.4M | 17.4M | 16.9M | 14.6M | 13.2M | 13.4M | 13.6M | 13.8M |
| 銷售管理費用 | 4.2M | 3.7M | 3.4M | 4.3M | 4.5M | 4.1M | 4.9M | 5.5M | 5.0M | 5.5M | 6.0M | 6.3M |
| 營業利益 | −18.9M-17% | −19.0M-12% | −19.2M-12% | −22.5M+12% | −22.9M+26% | −21.6M+14% | −21.9M+12% | −20.2M+0% | −18.2M | −18.9M | −19.6M | −20.1M |
| 營業利益率 | -2,396.1% | -1,940.7% | -1,561.8% | -1,521.8% | -1,353.8% | -1,114.4% | -837.0% | -720.1% | -617.2% | -597.0% | -657.8% | -746.4% |
| 稅後淨利 | −18.1M-15% | −18.0M+3% | −18.0M-6% | −21.1M+1636% | −21.2M+39% | −17.4M+11% | −19.2M+16% | −1.2M-93% | −15.3M | −15.8M | −16.6M | −17.4M |
| 淨利率 | -2,295.2% | -1,840.6% | -1,464.0% | -1,422.9% | -1,255.0% | -901.1% | -735.2% | -43.3% | -517.3% | -497.7% | -557.6% | -646.7% |
| 稀釋 EPS | -0.34-17% | -0.340% | -0.33-11% | -0.40+1900% | -0.41+37% | -0.34+13% | -0.37+9% | -0.02-95% | -0.30 | -0.30 | -0.34 | -0.38 |
| 稀釋股數 | 53.4M | 53.3M | 52.5M | 53.0M | 52.0M | 52.0M | 51.6M | 51.5M | 51.4M | 48.0M | 49.0M | 45.8M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 12.5M | 39.1M | 38.0M | 36.3M | 44.1M | 51.3M | 48.8M | 48.5M | 47.7M | 37.7M | 52.1M | 68.2M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 82.1M | 96.6M | 117M | 134M | 153M | 171M | 223M | 238M | 237M | 252M | 261M | 242M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 10.6M | 8.6M | 11.9M | 12.8M | 12.3M | 10.5M | 25.6M | 23.2M | 24.2M | 26.5M | 23.4M | 24.4M |
| 股東權益 | 71.5M | 88.0M | 105M | 121M | 141M | 160M | 198M | 214M | 213M | 226M | 238M | 218M |
| 負債比 | 12.9% | 8.9% | 10.2% | 9.6% | 8.0% | 6.2% | 11.4% | 9.8% | 10.2% | 10.5% | 9.0% | 10.1% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −19.7M+8% | – | – | – | −18.3M | – | – | −16.2M | – | – | – |
| 資本支出 | – | 0.00 | – | – | – | 4K | – | – | 594K | – | – | – |
| 自由現金流 | – | −19.7M+8% | – | – | – | −18.3M | – | – | −16.8M | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -2,008.1% | – | – | – | -944.2% | – | – | -568.4% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 6.3M | -40.5% | −77.7M | -1,226.8% | -1.48 | −73.6M |
| FY2024 | 10.7M | -4.6% | −58.9M | -552.8% | -1.14 | −51.9M |
| FY2023 | 11.2M | +208.0% | −69.0M | -617.3% | -1.44 | −56.6M |
| FY2022 | 3.6M | +707.8% | −73.3M | -2,021.4% | -1.61 | −71.7M |
| FY2021 | 449K | -31.0% | −57.8M | -12,883.3% | -1.28 | −47.9M |
| FY2020 | 651K | -50.0% | −34.4M | -5,290.3% | -2.40 | −32.9M |
| FY2019 | 1.3M | -3.0% | −25.4M | -1,948.7% | -8.35 | −22.2M |
| FY2018 | 1.3M | – | −17.5M | -1,307.8% | -5.82 | −15.6M |